11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Cinacalcet STADA

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Cinakalcet

Cinakalcet

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Mimpara (cinakalcet). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2017-04-09, cited 2019-07-22]

  2. US Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - SENSIPAR (cinacalcet). Drugs@FDA [www]. [updated 2004-03-08, cited 2019-07-22].

  3. Mimpara (cinakalcet) EPAR Scientific discussion. European Medicines Agency (EMA) [updated 2005-10-21, cited 2019-05-28]

  4. Sajid-Crockett S, Singer FR, Hershman JM. Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism. 2008;57(4):517-21.

  5. US Food and Drug Administration. Statistical review - SENSIPAR (cinacalcet). Drugs@FDA [www]. [updated 2004-03-08, cited 2019-07-22].

  6. US Food and Drug Administration. Medical review - SENSIPAR (cinacalcet). Drugs@FDA [www]. [updated 2004-03-08, cited 2019-07-22].

  7. Otsuka K, Ohno Y, Oshima J. Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Ren Fail. 2018;40(1):38-42.

  8. US National Library of Medicine. Sensipar (cinacalcet). DailyMed [www]. [updated 2012-05-01, cited 2019-07-22].

  9. Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS. The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial. Clin J Am Soc Nephrol. 2015;10(5):800-7.

  10. Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R et al. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. J Am Soc Nephrol. 2015;26(6):1466-75.

  11. Parfrey PS, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J et al. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. J Clin Endocrinol Metab. 2013;98(12):4834-44.

  12. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-08-19.]

  1. Mimpara (cinakalcet). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2017-04-09, cited 2019-07-22]
  2. US Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - SENSIPAR (cinacalcet). Drugs@FDA [www]. [updated 2004-03-08, cited 2019-07-22].
  3. Mimpara (cinakalcet) EPAR Scientific discussion. European Medicines Agency (EMA) [updated 2005-10-21, cited 2019-05-28]
  4. Sajid-Crockett S, Singer FR, Hershman JM. Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism. 2008;57(4):517-21.
  5. US Food and Drug Administration. Statistical review - SENSIPAR (cinacalcet). Drugs@FDA [www]. [updated 2004-03-08, cited 2019-07-22].
  6. US Food and Drug Administration. Medical review - SENSIPAR (cinacalcet). Drugs@FDA [www]. [updated 2004-03-08, cited 2019-07-22].
  7. Otsuka K, Ohno Y, Oshima J. Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Ren Fail. 2018;40(1):38-42.
  8. US National Library of Medicine. Sensipar (cinacalcet). DailyMed [www]. [updated 2012-05-01, cited 2019-07-22].
  9. Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS. The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial. Clin J Am Soc Nephrol. 2015;10(5):800-7.
  10. Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R et al. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. J Am Soc Nephrol. 2015;26(6):1466-75.
  11. Parfrey PS, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J et al. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. J Clin Endocrinol Metab. 2013;98(12):4834-44.
  12. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-08-19.]